Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.
[EN] C-LINKED INHIBITORS OF ENL/AF9 YEATS<br/>[FR] INHIBITEURS À LIAISON C D'AMPLIFICATEURS DE YEATS ENL/AF9
申请人:BRIDGE MEDICINES
公开号:WO2022240830A1
公开(公告)日:2022-11-17
Compounds of Formula I and pharmaceutical compositions comprising compounds of Formula I are disclosed. Methods for treating acute leukemias using the compounds of Formula I and pharmaceutical compositions comprising the same are also disclosed.
The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.